Ischemic and bleeding risk prediction: many scores, little solution


> Tullio Palmerini University of Bologna Italy

# **Conflict of interest**






# Meta-analysis on DAPT duration: 10 RCT with 31,666 patients









*Palmerini et al; Lancet 2015* 

## **ISAR REACT, SWEET, SMART 2, REACT 2**




## **EVENT trial**




Ndrepepa et al; JACC 2008

Lindsey et al; JACC Int 2009

## ACUITY trial




### ADAPT DES



Mehran et al; JACC 2010

#### Genereux et al; JACC 2015

## Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting




12 randomized studies with 34880 patients IPD for 6 randomized studies with 11473 patients

Palmerini et al, JACC 2017


# Bleeding related death and DAPT duration

#### A. Bleeding-related Deaths




Palmerini, T. et al. J Am Coll Cardiol. 2017;69(16):2011-22.

#### B. Non-Bleeding-related Deaths



# Tailored therapy to balance the risk of ischemic vs bleeding events



# Risk scores for DAPT duration after DES placement

	PRECISE-DAPT score	DAPT score	<u>.</u>
Time of use	At the time of coronary stenting	After 12 months of uneve	ntful DAPT
DAPT duration strategies assessed	Short DAPT (3-6 months) vs. Standard/long DAPT (12-24 months)	Standard DAPT (12 n vs. Long DAPT (30 mc	535 <sup>(h)</sup>
Score calculation*	HB attr 31-5 it 1055 410   WBC attr 31-5 it 1052 44 it 1052   Age store it 1052 14 it 1052 it 1052   Age store it 1052 it 1052 it 1052 it 1052   CrCI atom at it 1052 it 1052 it 1052 it 1052 it 1052   Prior it 101 it 101 it 101 it 1012 it 1012 it 1012 it 1012   Score 0 2 4 it 1012 it 1012 it 1012 it 1012 it 1012 it 1012	Age 275 65 to <75 <65 Cigarette smoking Diabetes mellitus MI at presentation Prior PCI or prior MI Paclitaxel-eluting stent Stent diameter <3 mm CHF or LVEF <30% Vein graft stent	-2 pt -1 pt 0 pt +1 pt +1 pt +1 pt +1 pt +1 pt +1 pt +2 pt +2 pt
Score range	0 to 100 points	-2 to 10 point	5
Decision making cut-off suggested	Score ≥25 → Short DAPT Score <25 → Standard/long DAPT	Score ≈2 → Long DAPT Score <2 → Standard DAPT	

## **PARIS** score

ABLE 4 Integer Risk Score for Major Blanding		TABLE I Integer Risk Score for Coronary Thrombatic Events	
Parameter	Score	Parameter	Score
ge, yrs		Diabetes mellitus	
<50	0	None	0
50-59	+1	Non-insulin-dependent	+1 -3
60-69	+2	Insulin-dependent	+3
70-79	+3	Acute coronary syndrome	
<b>⊵80</b>		No	0
Mi, kg/m²		Ves, Tri-riegative	+1
<25	+2	Yes, To-positive	+2
25-34.9	0	Current smoking	
=35	+2	Yes	+1
urient smoking		tio	0
Yes	+2	CrCl <50 mi/min	
No	0	Present	+2
nemia		Abuert	0
Present	+3	Prov PCI	
Absent	+3 0	Yes	+2
CL < 60 mil/min	-11-14 V	No	+2
Present	+2	Prior CABG	
Alment	0	Yes	+2
iple therapy on discharge	55/12	No	0
Yes	+2	572.0	
No	0	To - tropoom, other abbreviations as in Table L.	

# **DAPT SCORE: net benefit**

	Predictors of Myocardial Infarction or Stent Thrombosis <sup>b</sup>		Predictors of Moderate or Severe Bleeding <sup>c</sup>	
Predictors of Events <sup>a</sup>	HR (95% CI)	P Value	HR (95% CI)	P Value
Continued thienopyridine vs placebo	0.52 (0.42-0.65)	<.001	1.66 (1.26-2.19)	<.001
Myocardial infarction at presentation	1.65 (1.31-2.07)	<.001		
Prior PCI or prior myocardial infarction	1.79 (1.43-2.23)	<.001		
History of CHF or LVEF < 30%	1.88 (1.35-2.62)	<.001		
Vein graft stent	1.75 (1.13-2.73)	.01		
Stent diameter <3 mm	1.61 (1.30-1.99)	<.001		
Paclitaxel-eluting stent	1.57 (1.26-1.97)	<.001		
Cigarette smoking	1.40 (1.11-1.76)	.01		
Diabetes mellitus	1.38 (1.10-1.72)	.01		
Age, per 10 y			1.54 (1.34-1.78)	<.001
Peripheral arterial disease	1.49 (1.05-2.13)	.03	2.16 (1.46-3.20)	<.001
Hypertension	1.37 (1.03-1.82)	.03	1.45 (1.00-2.11)	.05
Renal insufficiency/failure	1.55 (1.03-2.32)	.04	1.66 (1.04-2.66)	.03

Yeh et al; JAMA 2016


## **The DAPT Score**



10

Points	Distribution of DAPT Scores among all
	randomized subjects in the DAPT Stud
	30%
-2	S OF OF
-1	25%
0	%02 <b>Bati</b>
1	<b>b</b> 15%
1	
1	00 <b>ercentag</b> 5%
2	<b>2</b> 5%
1	-2-10123456789
2	DAPT Score
1	
	-2 -1 0 1 1 2 1 2

## Continued Thienopyridine vs. Placebo High vs. Low DAPT Score



S

ΔΡΤ

# Limitation of the DAPT score


- The validation cohort is questionable (PROTECT trial)
- Post hoc analyses not powerd to examine differences between subgroups
- Mainly patients treated with clopidogrel
- Impossibility to stratify patients upfront
- Low discrimination power
- Several important variable missing (previous bleeding, baseline anemia,...)
- Results influenced by using of I generation DES


# PRECISE DAPT SCORE: focus on bleeding risk (TIMI major and minor)

	Hazard ratio (95% CI)	p value
Age (for each increase of 10 years)	1.34 (1.11-1.48)	0.005
Previous bleeding	4·14 (1·22–14·02)	0.023
White-blood-cell count (for each increase of 10 <sup>3</sup> cells per µL)	1.06 (0.99–1.13)	0.078
Haemoglobin at baseline (for each increase of 1 g/dL)	0.67 (0.53–0.84)	0.001
Creatinine clearance (for each increase of 10 mL/min)	0·90 (0·82–0·99)	0.004

Costa et al; Lancet 2017


# **Benefit vs harm with prolonged DAPT**






Costa et al; Lancet 2017

## **Uncertain ischemic boundary**




Yeh et al; JACC 2015



Giustino et al; JACC 2016

Cortisone therapy Anticoagulant therapy Thrombocytopenia Severe liver disease

12-month or 24-month DAPT vs 3-month or 6-month DAPT



# **PARIS DAPT score**

TABLE 4 Integer Risk Score for Major Bleeding		
Parameter BARC type 3 or \$	Score	
Age, yrs		
<50	0	
50-59	+1	
60-69	+2	
70-79	+3	
≥80	+4	
BMI, kg/m <sup>2</sup>		
<25	+2	
25-34.9	0	
>35	+2	
Current smoking		
Yes	+2	
No	0	
Anemia		
Present	+3	
Absent	0	
CrCl <60 ml/min		
Present	+2	
Absent	0	
Triple therapy on discharge		
Yes	+2	
No	0	


#### TABLE 5 Integer Risk Score for Coronary Thrombotic Events

Parameter	Score
Diabetes mellitus	
None	0
Non-insulin-dependent	+1
Insulin-dependent	+3
Acute coronary syndrome	
No	0
Yes, Tn-negative	+1
Yes In-positive	+2
Current smoking	
Yes	+1
No	0
CrCl <60 ml/min	
Present	+2
Absent	0
Prior PCI	
Yes	+2
No	0
Prior CABG	
Yes	+2
No	0


Tn = troponin; other abbreviations as in Table 1.

Baber et al; JACC 2016

## Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients




**1926 patients with ACS** 




10

6 Predicted BARC type 3 or 5 bleeding


## **Decision curve analysis**



# **Risk score vs clinical judgments**



# **Clinical judgement vs risk scores**



Palmerini and Stone; European Heart Journal 2016

# Conclusions

- Longer DAPT reduces the risk of MI and stent thrombosis, but increases the risk of bleeding and bleeding-related death.
- DAPT duration should therefore be individualized according to the ischemic and bleeding risk of indivitual patients
- There are three risk score created to tailor DAPT duration after DES placement, but they have several limitations (not all variables captured, dichotomic stratification).
- There are several nuances when balancing the risk of ischemic vs bleeding events that risk scores cannot capture and therefore their use should always be put after wise clinical judgement.